Loading...
01/11 12:37
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights several concerns: revised down revenue growth guidance for Pombiliti and Opfolda, competitive pressures, and economic challenges. Although there are positive elements like improved cash flow and reduced net loss, the unexpected rebate and delays in patient starts raise uncertainties. Management's vague responses about future impacts further cloud investor confidence. Given the company's small market cap and these mixed signals, a negative stock price reaction is expected.
Total Revenue $125.2 million, up 13% year-over-year; growth driven by strong performance in core business areas.
Galafold Revenue $104.2 million, up 6% at constant exchange rates; growth attributed to a 14% increase in new patient starts globally.
Pompe Disease Revenue (Pombiliti and Opfolda) $21 million, up 92% at constant exchange rates; growth driven by initial launch countries, particularly the U.S., Germany, and Spain.
Cost of Goods Sold (COGS) 9.3% of net sales, down from 12.3% year-over-year; improvement due to better supply chain management.
GAAP Operating Expenses $121.5 million, down 2% year-over-year; decrease attributed to financial discipline.
Non-GAAP Operating Expenses $94.5 million, up 10% year-over-year; increase due to ongoing R&D commitments and the upfront licensing fee for DMX-200.
Net Loss (GAAP) $21.7 million or $0.07 per share, improved from a net loss of $48.4 million or $0.16 per share year-over-year; improvement due to revenue growth.
Non-GAAP Net Income $9 million or $0.03 per share, compared to a non-GAAP net loss of $4.6 million or $0.02 per share year-over-year; driven by revenue growth.
Cash, Cash Equivalents, and Marketable Securities $251 million at March 31, 2025, compared to $25 million at December 31, 2024; significant increase due to improved cash flow.
Galafold Revenue: Revenue reached $104.2 million, up 6% at constant exchange rates, with new patient starts globally up 14%.
Pombiliti and Opfolda Revenue: Revenue reached $21 million, up 92% at constant exchange rates, primarily driven by the US, Germany, and Spain.
DMX-200 Licensing Agreement: Entered a licensing agreement with Dimerix for DMX-200, a first-in-class treatment for FSGS, with a $30 million upfront payment.
Market Share for Galafold: Achieved over 69% of the global market share of treated Fabry patients with amenable mutations.
Geographic Expansion: Revenue recorded in 7 countries, with new patient starts expected in Italy, Czech Republic, Portugal, and Netherlands.
Supply Chain Diversification: Onshoring a portion of drug product manufacturing to enhance diversification strategy.
Cost Management: Cost of goods sold as a percentage of net sales decreased to 9.3% from 12.3% year-over-year.
GAAP Profitability: On track to achieve GAAP profitability in the second half of 2025.
Leadership Change: Mike Cavany retired; Gwen Whitney appointed as new President of U.S. business.
Regulatory Issues: Amicus is responsible for submission and maintenance of the regulatory dossier in the United States for DMX-200, which adds complexity and potential delays in the commercialization process.
Supply Chain Challenges: Despite proactive supply chain planning, there are ongoing concerns regarding tariffs and their potential impact on business operations. However, the company has managed to neutralize exposure to tariffs this year.
Revenue Guidance Adjustments: The revenue growth guidance for Pombiliti and Opfolda has been revised down from 65%-85% to 50%-65%, indicating potential challenges in achieving previous sales expectations.
Market Competition: The company faces competitive pressures in the rare disease market, particularly with the introduction of new therapies and the need to maintain market share against other established treatments.
Economic Factors: The overall economic environment in biotech has been described as tumultuous, which may affect investor confidence and market conditions for fundraising and partnerships.
Strategic Collaboration: Entered into a strategic collaboration with Dimerix for U.S. commercialization rights to a first-in-class compound in late Phase III development for a rare kidney disease.
Supply Chain Diversification: Strengthening and diversifying supply chain by onshoring a portion of drug product manufacturing from Pombiliti.
Market Expansion: Plans to launch Pombiliti and Opfolda in up to 10 new countries in 2025.
Patient Access: Secured broad patient access throughout the EU and received regulatory approvals in Australia and Canada.
Revenue Growth Guidance: Total revenue growth guidance updated to 15% to 22% from previous 17% to 24%.
Galafold Revenue Growth Guidance: Reiterated Galafold revenue growth guidance of 10% to 15%.
Pombiliti and Opfolda Revenue Growth Guidance: Revised revenue growth guidance to 50% to 65% from previous 65% to 85%.
GAAP Profitability: Anticipate achieving positive GAAP net income during the second half of 2025.
Combined Sales Projection: Expect combined sales of Galafold and Pombiliti/Opfolda to reach $1 billion by the end of 2028.
Upfront Payment for Licensing Agreement: $30 million paid from Amicus cash on hand for the licensing agreement with Dimerix.
Revenue Growth Guidance: Total revenue growth guidance updated to 15% to 22% for 2025.
Non-GAAP Operating Expense Guidance: Expected to be $380 million to $400 million, including the $30 million upfront license payment.
GAAP Profitability: Anticipated positive GAAP net income during the second half of 2025.
Combined Sales Projection: Confidence that Galafold and Pombiliti will reach combined sales of $1 billion by the end of 2028.
The earnings call highlights strong financial performance, with significant revenue growth and a shift to GAAP profitability. Despite increased COGS, net income improved, and cash reserves grew. The Q&A section revealed positive reception of product labels and strategic market expansion plans. However, vague responses on revenue acceleration and supply stability pose some concerns. Overall, the positive financial results, optimistic guidance, and strategic initiatives outweigh these concerns, suggesting a positive stock price movement.
The earnings call reveals mixed signals. Financial performance shows increased expenses and net loss, though non-GAAP income remains positive. Product development and market expansion are promising, with strong market share gains and regulatory progress. However, the decreased revenue growth guidance and increased COGS raise concerns. The Q&A highlights confidence in IP and manufacturing progress but lacks specifics on timelines and COGS impact. Overall, the sentiment is neutral, with potential for both positive and negative market reactions.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
